CLINICAL TRIALS & RESEARCH

Respiratory Department conducts internationally recognized clinical research into the latest management of respiratory illness from our Clinical Trials Unit (CTU). Our research focuses on assessing the benefits of new medications and approaches to therapy for patients with asthma, COPD, bronchiectasis and lung cancer.

Clinical Trials Q & A's

What is a clinical trial?

A clinical trial is a study designed to answer specific questions about new medications or therapies for a specific health condition such as asthma, COPD or lung cancer. Clinical trials are used to determine whether new drugs or treatments are both safe and effective, and are the fastest and safest way to develop new treatments that work for people.

If I am randomised, what does it mean?

Randomisation is the allocation of of participants to either the placebo or active treatment group, and is done by chance (like flipping a coin). Study participants cannot choose whether to take the active drug or placebo. It is used to eliminate the possibility of bias.

What does "placebo-controlled" mean?

A placebo is a dummy treatment, such as sugar tablet or saline which looks, smells and tastes exactly like the real thing but contains no active ingredients. The placebo-effect is a well known phenomenon where people being closely monitored or studied tend to feel better because of the attention they receive and the belief that they are being treated. The placebo effect can be very strong so the effects of a new drug must be proven to be greater than this.

Placebos are used in clinical trials to show that any effects that are measured during a trial really are due to the drug being studied. Participants in a trial will not know whether they are taking the real drug or the placebo and usually neither will the study staff.

Placebo-controlled trials are considered the gold standard and therefore most Phase I, II and III trials will include a placebo group.

What does "double-blind" mean?

This means that neither the staff running the study nor the study participants know whether they are taking the real medication or the placebo. It is used to eliminate bias by ensuring that neither the participant nor the study staff are influenced in their interpretation of the study results.

At the end of the study, the "blind" is broken to reveal who was taking the active treatment to allow conclusions to be drawn about the drug effectiveness and safety. In an emergency, the study doctor is able to find out which treatment a person is taking.

What will I be asked to do?

Depending on the type of study, you will be asked to do different things, but the most common things are taking your medication as it is prescribed, attending visits at the clinic at pre-arranged times, keeping a daily diary of your symptoms, and ensuring that you contact us immediately if you are unwell or have any concerns.

How long will I be on the study?

Some of our studies only go for a month or two, and others last for up to a year. You will be told how long the study lasts the first time you contact us for information about the trial. The number of visits to the Unit's clinic can also vary quite a bit, some studies have a visit every week, and others might be every few months.

What if I need to change an appointment?

We will try and book all your visits when you first come in to see us, so that you can plan in advance. However, if you need to change an appointment, simply call the Unit as early as possible and we will try to reschedule.

What if I change my mind about being in the study?

All of our studies are voluntary, so you can decide not to participate and you don't have to tell us why. Even if you join the study, you can still change your mind and withdraw at any time. Again, you don't have to give us a reason, but we may ask you to come in for a final visit to do some safety checks.

What if something happens to me while I am on the study?

Monitoring new medications to ensure that they are safe and have few side effects is an important aspect of any clinical drug trial. During the study you will be regularly assessed for any potential side effects of the study drug. You should always contact the Unit's clinic if you think you are experiencing side effects. If they are severe enough, the doctor may temporarily stop study medication, reduce the dose, or withdraw the medication completely. In the unlikely event that you become unwell from taking part in this trial, you will be provided with the necessary medical care at no cost.

Will I be paid for being on the study?

While we are unable to provide payment for participation on a trial, we can usually offer reimbursement for your travel expenses. Depending on the trial, if the visits are very long you may be provided with a meal and compensation for lost time and inconvenience.

What are some of the procedures I might be asked to do?

Common procedures you will be asked to do include:

• Physical examinations and vital signs (blood pressure, heart rate and breathing rate measurements);
• Electrocardiograms (ECG), which are electrical recordings of how your heart is working. This procedure does not hurt;
• Lung function measurements, which will be done with a machine called a spirometer. You are asked to breathe into a mouthpiece and this will measure your lung capacity;
• Questionnaires about your health problems and general well being;
• Blood samples are commonly required and we usually need about 10 mls (4 teaspoons). This is taken from a vein in your arm. Occasionally some trials require multiple blood tests during the same visit;
• Urine samples are often collected for routine urinalysis testing. You will be asked to provide a sample during your visit;
• Pregnancy tests, if you are female and of child bearing potential, your blood and urine samples may also be used to test for pregnancy. It is very important that you do not become pregnant during a study, so if you are thinking of becoming pregnant, or are breast feeding, you will not be able to be involved in a clinical trial; and
• In some studies chest x-rays or CTscans, may be required to ensure that your lungs are otherwise healthy. These tests do not hurt.

Can I be involved in more than one study?

You can only be on one clinical trial at a time; however you would always be welcome to join another study after you have finished a trial.

What does it mean if I am not eligible for a study?

Because we want to ensure that the data we gather about a new medication is as accurate as possible, we select participants using eligibility criteria that will ensure we get the best answers. So the best matched participants are chosen for the right trial, the rules are often strict and may factor in age, other medical conditions, or how good or bad your lung function is. If you are not eligible for a study it does not mean that you have ‘failed', and you may always be eligible for another study.

Can I tell people that I am on a clinical trial?

It is your decision if you want to tell people that you are on a clinical trial. We encourage you to speak with family and your doctor if you are considering participating in a study. However, we will keep all your information confidential.

If you are interested in participating in any trials or would simply like more information, please contact the CTU. Telephone: 088 – 474775 or email to: jabatanrespiratorihqe@gmail.com

Dr Jamalul Azizi presented 2 research papers, wrote 2 case reports and participated in 2 large clinical trials from year 2000 to 2003:
  1. Factors influencing carbon monoxide transfer factor in asthma and bronchiectasis - Oral presentation at the 8th Asian Pacific Society of Respirology Congress 1-4 December 2003, Sunway Lagoon, Petaling Jaya, Malaysia. Poster presentation at the TSANZ Annual Scientific Meeting 19-24 March 2004, Sydney, Australia (Respirology Volume 9 Supplement March 2004 Page A39)
  2. Comparison of respiratory function in bronchiectasis and allergic bronchopulmonary aspergillosis (ABPA) - Poster presentation at the TSANZ Annual Scientific Meeting 19-24 March 2004, Sydney, Australia (Respirology Volume 9 Supplement March 2004 Page A38)
  3. A case of pulmonary alveolar proteinosis treated with GM-CSF - Respirology 2004 Volume 9, Page 419-422
  4. A case of alpha1 antitrypsin deficiency in an 81-year old life time non-smoker - Poster presentation at the 8th Malaysian Thoracic Society Congress 15-17 July 2005, Kuala Lumpur, Malaysia
  5. SYMBIOSIS STUDY - 1-year international, randomised, double-blind, placebo-controlled prospective study aimed to test whether the short-term improvement in COPD that follows a period of treatment intensification with oral prednisolone and inhaled formoterol could be maintained over a longer time by treatment with Symbicort, budesonide, formoterol or placebo. Eur Respir J 2003;22:912–919.
  6. TORCH STUDY (TOwards a Revolution in COPD Health) - 3-year multicentre, placebo-controlled, double-blind, randomised, parallel-group trial aimed to determine the impact of salmeterol/fluticasone propionate (SFC) combination and the individual components on the survival of COPD patients. Am J Respir Crit Care Med 2008; 178:332-338

Since the establishment of the respiratory department in Sabah in June 2005, we have either produced or conducted the following clinical trials and research papers. We also receive invitation to review manuscripts from Asia Pacific countries:

  1. Double blind, double dummy, multinational, multicenter, parallel-group design clinical trial of superiority of CHF 1535 1 puff in a b.i.d regimen administered via an HFA-propellant-pMDI versus a double equivalent dose of Beclomethasone Dipropionate in a b.i.d regimen administered via an CFC-propellant-pMDI in a 12 week treatment period of mild to moderate persistent asthma in adult patients
  2. Quit Smoking Clinic Service in Sabah:Management Strategy. Presented at the 2007 Asia Regional Alliance for Smoking Cessation Meeting in Seoul, South Korea 27-29 April, 2007. Joseph Lee Han Kyun, Jamalul Azizi
  3. A 12-week, double-blind, randomised study to investigate the effect of 500ug roflumilast tablets once daily versus placebo on pulmonary function in patients with chronic obstructive pulmonary disease
  4. Randomised, 4-week placebo-controlled, double blind, 6 arm parallel group, dose-finding clinical trial to assess the efficacy, safety and pharmacokinetics of three different doses of formoterol (6, 12 & 18 ug) combined with the inhaled anticholinergic aclidinium bromide 200ug, aclidinium bromide 200ug monotherapy and formoterol 12ug monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease
  5. Open label, randomised, parallel group, multicentre, phase III study to assess efficacy, safety and tolerability of Gefitinib (IRESSA)(250mg tablet) versus Carboplatin/Paclitaxel Doublet Chemotherapy as First-line Treatment in selected patients with advanced (stage IIIB or IV) Non-Small Cell Lung Cancer (NSCLC) in Asia (IPASS study)
  6. Medical thoracoscopy (pleuroscopy) in East Malaysia: Early experience. Presented at the 15th World Congress for Bronchology and 15th World Congress for Bronchoesophagology in Tokyo, Japan on April 1, 2008. ST Tie, JL Wong, Kunji Kannan, Jamalul Azizi.
  7. Randomised double-blind, double-dummy, placebo-controlled, parallel group study to assess the efficacy and safety of 48 weeks of once daily treatment of orally inhaled BI 1744 CL (5uG[2 actuations of 2.5uG] and 10 G [2 actuations of 5uG] delivered by the Respimat inhaler, and 48 weeks of twice daily Foradil (12uG) delivered by the Aerolizer inhaler, in patients with chronic obstructive pulmonary disease - on going
  8. Pulmonary myopericytoma: a case report and review of the literatures (manuscript review by Dr Jamalul Azizi) - Chinese Medical Journal 2009;122(6):755-757
  9. Diagnosis and management of intractable haemoptysis by bronchoscopic intervention (manuscript review by Dr Jamalul Azizi) - Respirology